Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients with Oesophageal Squamous Cell Cancer By Ogkologos - April 23, 2025 570 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a biomarker analysis from the RATIONALE-302 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR FDA Approval of KRAS Inhibitor Sotorasib for Lung Cancer Hailed as... June 25, 2021 Personalised blood test could help predict which lung cancers might return April 1, 2022 Genetic Cancer Screenings in Younger Women May Be Cost-Effective and Lead... November 26, 2020 Combining Radiotherapy with SOC Plus Abiraterone Improves rPFS in Patients with... December 5, 2024 Load more HOT NEWS Antibody Drug Ejects Problematic Proteins from Cancer Cells EMA Recommends Extension of Therapeutic Indications for Tisagenlecleucel Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients... FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC
